Skip to Content
  • Beta-Amyloid: An Antibiotic?

    Now here’s something that I don’t think anyone expected. A recent paper in PLoS One makes the case that beta-amyloid, the protein that has been fing… Read More
  • Dimebon, Grasping at Straws

    Robert Langreth, an editor at Forbes, points to a possible way that Dimebon could get approval for Alzheimer’s: for its behavioral effects, not anything t… Read More
  • Dimebon Comes Crashing to Earth

    Earlier this month I wrote about Medivation and their Russian-derived clinical candidate for Alzheimer’s disease, Dimebon (latrepirdine). At the time, I w… Read More
  • A Modest Literature Proposal

    Looking through the latest papers to show up in the Journal of Medicinal Chemistry, this one on BACE-1 inhibitor compounds caught my eye. Perhaps I’m abou… Read More
  • Two Doses of Crazy

    I’d like to take the time this morning to deal with two conspiracy theorists, and I’ll take them in order of increasing foil-hat thickness. First up… Read More
  • Short Topics From All Over

    (1) Bnet Pharma on “How Not to Write a Pharma Press Release“. Privately held Epeius is sending out bulletins loaded with phrases like “more st… Read More
  • Amyloid in Trouble

    Here’s an interesting look at the current state of the Alzheimer’s field from Bloomberg. The current big hope is Wyeth (and Elan)’s bapineuzum… Read More
Page 10 of 13« First...89101112...Last »